Nigericin
Nigericin is an antibiotic derived from Streptomyces hygroscopicus that act as a K+/H+ ionophore, promoting K+/H+ exchange across mitochondrial membranes. Nigericin is a NLRP3 activator. Nigericin shows promising anti-cancer activities through decreasing intracellular pH (pHi), and inactivation of Wnt/β-catenin signals. Nigericin induces pyroptosis through caspase 1/GSDMD in TNBC[1][2][3][4][5][6][7].
Product Specifications
CAS Number
[28380-24-7]
UNSPSC
12352005
Hazard Statement
H301, H315, H319, H335
Target
Antibiotic; Bacterial; NOD-like Receptor (NLR) ; Potassium Channel; Pyroptosis; Wnt; β-catenin
Type
Reference compound
Related Pathways
Anti-infection; Apoptosis; Immunology/Inflammation; Membrane Transporter/Ion Channel; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Infection
Assay Protocol
https://www.medchemexpress.com/nigericin.html
Purity
99.43
Solubility
DMSO : < 1 mg/mL (ultrasonic; warming; heat to 60°C) |Ethanol : ≥ 33.33 mg/mL
Smiles
C[C@H]1[C@](O[C@@H]2C[C@](CC[C@@H]3C)([H])O[C@@]3([H])[C@@H](C)C(O)=O)([C@@H]([C@H](OC)C2)C)O[C@](C)([C@]4([H])O[C@](C)([C@]5([H])O[C@]([C@@]([C@H](C[C@H]6C)C)([H])O[C@@]6(O)CO)([H])C[C@@H]5C)CC4)C1
Molecular Formula
C40H68O11
Molecular Weight
724.96
Precautions
H301, H315, H319, H335
References & Citations
[1]Zotova L, et al. Novel components of an active mitochondrial K (+) /H (+) exchange. J Biol Chem. 2010 May 7;285 (19) :14399-414.|[2]Mariathasan S, et al.Cryopyrin activates the inflammasome in response to toxins and ATP.Nature. 2006 Mar 9;440 (7081) :228-32.|[3]Bissinger R, et al. Triggering of Suicidal Erythrocyte Death by the Antibiotic Ionophore Nigericin. Basic Clin Pharmacol Toxicol. 2016 May;118 (5) :381-9.|[4]Xiaoli Zhu, et al. Nigericin is effective against multidrug resistant gram-positive bacteria, persisters, and biofilms. Front Cell Infect Microbiol. 2022 Dec 20:12:1055929.|[5]Guanzhuang Gao, et al. Evidence of nigericin as a potential therapeutic candidate for cancers: A review. Biomed Pharmacother. 2021 May:137:111262.|[6]Lisha Wu, et al. Nigericin Boosts Anti-Tumor Immune Response via Inducing Pyroptosis in Triple-Negative Breast Cancer. Cancers (Basel) . 2023 Jun 16;15 (12) :3221.|[7]Juan Sebastian Yakisich, et al. Nigericin decreases the viability of multidrug-resistant cancer cells and lung tumorspheres and potentiates the effects of cardiac glycosides. Tumour Biol.2017 Mar;39 (3) :1010428317694310.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
NLRP3
Citation 01
ACS Infect Dis. 2025 Oct 10;11 (10) :2739-2753.|Aging (Albany NY) . 2021 Aug 25;13 (16) :20534-20551.|Am J Chin Med. 2020;48 (7) :1693-1713.|Am J Reprod Immunol. 2025 Aug;94 (2) :e70132.|Anal Chim Acta. 2025 Feb 15:1339:343637.|Bioact Mater. 2022 Jul 20:25:701-715.|Biochem Biophys Res Commun. 2020 May 7;525 (3) :759-766.|Biochem Pharmacol. 2022 Apr:198:114938.|Biochem Pharmacol. 2023 Jul:213:115599.|Biochem Pharmacol. 2025 Feb 12:234:116801.|Biochim Biophys Acta Mol Cell Res. 2024 Apr;1871 (4) :119689.|Biogerontology. 2025 Jan 31;26 (2) :49.|Biomater Res. 2025 Nov 6:29:0278.|Biomaterials. 2022 Dec:291:121888.|Biomaterials. 2024 Mar:305:122466.|Biomed Pharmacother. 2022 Jul;151:113098.|bioRxiv. 2024 September 07.|Biosci Biotechnol Biochem. 2024 May 8:zbae058.|Brain Behav. 2020 Jun;10 (6) :e01627.|Cancer Sci. 2024 Jul;115 (7) :2444-2460.|Cell Biol Toxicol. 2023 Jun;39 (3) :885-906.|Cell Commun Signal. 2024 Nov 25;22 (1) :565.|Cell Commun Signal. 2025 Jan 6;23 (1) :6.|Cell Death Differ. 2022 Feb;29 (2) :439-450.|Cell Death Dis. 2022 Apr 19;13 (4) :372.|Cell Death Dis. 2024 Jan 18;15 (1) :66.|Cell Death Dis. 2020 Feb 18;11 (2) :132. |Cell Death Discov. 2021 Feb 10;7 (1) :31.|Cell Death Discov. 2025 Nov 10;11 (1) :520.|Cell Host Microbe. 2023 Nov 8;31 (11) :1820-1836.e10.|Cell Metab. 2020 May 5;31 (5) :892-908.e11.|Cell Microbiol. 2022.|Cell Rep. 2024 Dec 12;43 (12) :115065.|Cell Res. 2023 Nov;33 (11) :835-850.|Cells. 2025 Oct 15;14 (20) :1601.|Chem Biol Interact. 2024 Dec 1:404:111262.|Chin J Integr Med. 2023 Jan;29 (1) :37-43.|Clin Cosmet Investig Dermatol. 2024 May 14:17:1093-1105.|Clin Transl Med. 2024 Mar;14 (3) :e1623.|Clin Transl Med. 2025 Feb;15 (2) :e70243.|Ecotoxicol Environ Saf. 2023 Jan 1:249:114359.|Environ Toxicol. 2023 Jun;38 (6) :1405-1419.|Eur J Pharmacol. 2025 May 26:1001:177774.|Exp Ther Med. 2021 Oct;22 (4) :1046.|Fish Shellfish Immunol. 2024 Aug 13:109837.|Free Radic Biol Med. 2025 Sep 11:S0891-5849 (25) 00976-1.|Front Immunol. 2021 Jul 7:12:688674.|Genes Dis. 2022 Jun 20;10 (4) :1552-1563.|Immun Inflamm Dis. 2023 Oct;11 (10) :e1043.|Inflamm Res. 2024 Dec;73 (12) :2069-2085.|Inflamm Res. 2024 Nov;73 (11) :1981-1994.|Int Immunopharmacol. 2021 Mar:92:107352.|Int Immunopharmacol. 2022 Dec;113 (Pt A) :109321.|Int Immunopharmacol. 2022 Oct:111:109098.|Int Immunopharmacol. 2023 Jul:120:110292.|Int Immunopharmacol. 2024 Dec 9:145:113781.|Int Immunopharmacol. 2024 Mar 30:130:111649.|Int Immunopharmacol. 2025 Apr 24:153:114504.|Int Immunopharmacol. 2025 Aug 19:164:115386.|Int Immunopharmacol. 2025 May 15:158:114820.|Int J Biol Macromol. 2025 Apr 14:143129.|Int J Biol Sci. 2024 Jan 1;20 (2) :733-750.|Int J Med Sci. 2020 Jun 29;17 (11) :1652-1664.|iScience. 2025 Jul 7;28 (8) :113067.|J Adv Res. 2025 Jul 14:S2090-1232 (25) 00544-2.|J Am Heart Assoc. 2022 Jul 5;11 (13) :e025266.|J Cardiothorac Surg. 2024 May 10;19 (1) :283.|J Cell Mol Med. 2020 Jul;24 (14) :8078-8090.|J Cell Mol Med. 2021 Nov;25 (21) :10268-10278.|J Ethnopharmacol. 2022 Jan 30:283:114694.|J Extracell Vesicles. 2023 Feb;12 (2) :e12310.|J Med Chem. 2024 Oct 10;67 (19) :17833-17854.|J Mol Histol. 2025 Aug 8;56 (4) :261.|J Nanobiotechnology. 2023 Aug 14;21 (1) :269.|J Neuroimmune Pharmacol. 2025 May 8;20 (1) :52.|J Neuroinflammation. 2021 Jun 24;18 (1) :142.|J Ovarian Res. 2024 Nov 26;17 (1) :236.|J Pharm Pharmacol. 2024 Mar 4;76 (3) :213-223.|J Toxicol Sci. 2023;48 (3) :139-148.|J Virol. 2023 Dec 21;97 (12) :e0133823.|Life Sci. 2023 Dec 1:334:122176.|Life Sci. 2026 Jan 1:384:124108.|Metab Brain Dis. 2022 Apr;37 (4) :1145-1154.|Mol Biol Rep. 2025 Apr 21;52 (1) :407.|Mol Biomed. 2025 Nov 13;6 (1) :108.|Mol Immunol. 2023 Mar:155:7-16.|Mol Immunol. 2024 Feb:166:79-86.|Mol Med. 2025 Feb 9;31 (1) :53.|Mol Med. 2025 Jan 27;31 (1) :27.|Mol Neurobiol. 2021 Dec;58 (12) :6520-6539.|Naunyn Schmiedebergs Arch Pharmacol. 2025 Jul;398 (7) :8947-8962.|Oxid Med Cell Longev. 2022 Feb 7;2022:9030771.|PeerJ. 2022 Oct 4:10:e14109.|PeerJ. 2023 Feb 13:11:e14826.|Pharm Biol. 2022 Dec;60 (1) :535-542.|Pharmacogn Mag. 2025 Feb 13.|Physiol Res. 2025 Apr 30;74 (2) :301-312. |Phytomedicine. 2023 May:113:154743.|Phytomedicine. 2025 Apr:139:156563.|Phytother Res. 2021 Jun;35 (6) :3406-3417.|PLoS Pathog. 2024 Jul 22;20 (7) :e1012398.|Probiotics Antimicrob Proteins. 2025 Jun 6.|Proc Natl Acad Sci U S A. 2024 Nov 12;121 (46) :e2406555121.|Proc Natl Acad Sci U S A. 2025 Jul 15;122 (28) :e2501347122.|Prostaglandins Other Lipid Mediat. 2024 Sep 9:106904.|Redox Biol. 2025 Sep 22:87:103877.|Rejuvenation Res. 2025 Sep 15.|Research Square Preprint. 2023 Apr 12.|Research Square Preprint. 2024 Feb 12.|Sci Adv. 2025 Jun 27;11 (26) :eadu3919.|Sci Rep. 2025 Apr 10;15 (1) :12278.|Shock. 2023 Jul 1;60 (1) :92-99.|Signal Transduct Target Ther. 2025 Nov 28;10 (1) :388.|SSRN. 2025 Aug 7.|Ther Adv Med Oncol. 2021 Jan 21:13:1758835920987056.|Tissue Cell. 2024 Dec:91:102588.|Tissue Cell. 2025 Sep 22:98:103152.|Tissue Eng Regen Med. 2024 Oct;21 (7) :1061-1077.|Vet Res. 2025 Oct 16;56 (1) :199.|Viruses. 2022 Aug 6;14 (8) :1734.|World J Tradit Chin Med. 2025 Oct 28.|Acta Pharmacol Sin. 2021 Nov;42 (11) :1913-1920.|Acupunct Herb Med. 2024 Nov 12.|Aging Cell. 2025 Apr 7:e70061.|Appl Microbiol Biotechnol. 2017 May;101 (10) :4201-4213.|Biomed Pharmacother. 2024 Jul 12:177:117121.|Biomed Rep. 2025.|bioRxiv. 2025 March 28.|Brain Res. 2024 Jul 10:149121.|Brain Res. 2024 Sep 1:1838:148975.|Cancer Lett. 2024 Apr 28:588:216797.|Cell Death Differ. 2022 Oct;29 (10) :2009-2023.|Cell Death Dis. 2021 Dec 14;12 (12) :1159.|Cell Rep. 2025 Jul 22;44 (7) :115922.|Cell Rep. 2025 Jul 26;44 (8) :116076.|Cell Rep. 2019 May. |Clin Transl Med. 2025 Mar;15 (3) :e70263.|CNS Neurosci Ther. 2022 Mar;28 (3) :390-400.|CNS Neurosci Ther. 2025 Nov;31 (11) :e70620.|Crit Care. 2021 Oct 12;25 (1) :356.|Cytotechnology. 2025 Apr;77 (2) :72.|Dev Cell. 2025 May 5;60 (9) :1336-1347.e5.|Eur J Med Chem. 2023 Jan 5;245 (Pt 2) :114919.|Front Microbiol. 2020 Apr 30;11:790.|Inflammation. 2021 Jun;44 (3) :1023-1034.|Inflammation. 2024 Oct;47 (5) :1744-1761.|Int Immunopharmacol. 2024 Jun 7:136:112346.|Int Immunopharmacol. 2025 Sep 26:166:115601.|Int J Mol Med. 2021 Dec;48 (6) :219.|iScience. 2021 Sep 25;24 (10) :103170.|J Agric Food Chem. 2024 Jun 10.|J Am Chem Soc. 2022 Oct 26;144 (42) :19396-19409.|J Biol Chem. 2022 Jan;298 (1) :101532.|J Ethnopharmacol. 2024 Aug 17:118661.|J Exp Med. 2022 Oct 3;219 (10) :e20212117.|J Exp Med. 2023 Mar 6;220 (3) :e20221316.|J Funct Foods. 2023, 100: 105386.|J Funct Foods. December 2020, 104274.|J Gastroenterol. 2024 Sep;59 (9) :869-879.|J Neuroinflammation. 2022 Sep 28;19 (1) :237.|J Pharm Pharmacol. 2024 Jul 10:rgae077.|Life Sci. 2021 Oct 1:282:119814.|Mater Today Bio. 2025 May 10:32:101838.|Metab Brain Dis. 2022 Feb;37 (2) :329-341.|Mol Cell Biochem. 2024 Jan;479 (1) :63-72.|Mol Immunol. 2020 Apr 13;122:28-37.|Molecules. 2022 Apr 12;27 (8) :2488.|Nat Commun. 2025 Jul 18;16 (1) :6621.|Nat Commun. 2025 Jul 2;16 (1) :6074.|Nat Immunol. 2025 Oct;26 (10) :1660-1672.|Neurosci Bull. 2025 May 24.|Oncotarget. 2018 Jan 13;9 (13) :10868-10879. |Open Res Eur. 2025.|Oxid Med Cell Longev. 2023 Jan 12:2023:3317307.|Parasit Vectors. 2022 Sep 23;15 (1) :334.|Phytomedicine. 2023 Aug:117:154922.|Phytomedicine. 2024 May 28:131:155758.|Phytomedicine. 2025 Sep:145:157041.|Res Sq. 2025 Jul 20.|Research Square Preprint. 2021 Jul.|Research Square Preprint. 2023 Aug 31.|Research Square Preprint. 2024 Aug 26.|Sci Rep. 2025 Apr 17;15 (1) :13280.|Sensor Actuat B-Chem. 297 (2019) 126801.|Signal Transduct Target Ther. 2024 Dec 30;9 (1) :367.|Signal Transduct Target Ther. 2025 Jul 3;10 (1) :209.|SSRN. 2023 Oct 30.|SSRN. 2025 Nov 5.|Transl Res. 2022 Sep:247:39-57.|World J Tradit Chin Med. 2024 Apr 12.
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
